The english version of the website is under development. Wherever text appears in Greek, it means it has not been translated yet.

Publications

Κατάλογος ενδεικτικών δημοσιεύσεων του τμήματος Ιατρικής ΑΠΘ σε διεθνή επιστημονικά περιοδικά κατά τα τελευταία 5 έτη.

Export 369 results:
Author [ Title(Desc)] Type Year
Filters: Author is Polyzos, Stergios A  [Clear All Filters]
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 
C
Polyzos, S. A., Aronis K. N., Kountouras J., Raptis D. D., Vasiloglou M. F., & Mantzoros C. S. (2016).  Circulating leptin in non-alcoholic fatty liver disease: a systematic review and meta-analysis.. Diabetologia. 59(1), 30-43.
Makri, E. S., Evripidou K., & Polyzos S. A. (2024).  Circulating leptin in patients with nonalcoholic fatty liver disease-related liver fibrosis: a systematic review and a meta-analysis.. J Gastroenterol Hepatol.
Anastasilakis, A. D., Polyzos S. A., Makras P., Rauner M., Sonnleitner L., Hawa G., et al. (2019).  Circulating noggin levels following treatment with denosumab or teriparatide in postmenopausal women with low bone mass.. J Musculoskelet Neuronal Interact. 19(3), 253-257.
Sakellariou, G. T., Anastasilakis A. D., Bisbinas I., Oikonomou D., Gerou S., Polyzos S. A., et al. (2015).  Circulating periostin levels in patients with AS: association with clinical and radiographic variables, inflammatory markers and molecules involved in bone formation.. Rheumatology (Oxford). 54(5), 908-14.
Polyzos, S. A., Anastasilakis A. D., Kountouras J., Makras P., Papatheodorou A., Kokkoris P., et al. (2016).  Circulating sclerostin and Dickkopf-1 levels in patients with nonalcoholic fatty liver disease.. J Bone Miner Metab. 34(4), 447-56.
Anastasilakis, A. D., Polyzos S. A., Yavropoulou M. P., Ntenti C., Mandanas S., & Makras P. (2021).  Circulating sclerostin levels during denosumab discontinuation and the subsequent early or late zoledronate infusion.. Endocrine.
Anastasilakis, A. D., Polyzos S. A., Makras P., Gkiomisi A., Sakellariou G., Savvidis M., et al. (2015).  Circulating semaphorin-4D and plexin-B1 levels in postmenopausal women with low bone mass: the 3-month effect of zoledronic acid, denosumab or teriparatide treatment.. Expert Opin Ther Targets. 19(3), 299-306.
Potoupni, V., Georgiadou M., Chatzigriva E., Polychronidou G., Markou E., Gakis C. Zapantis, et al. (2021).  Circulating tumor necrosis factor-α levels in non-alcoholic fatty liver disease: A systematic review and a meta-analysis.. J Gastroenterol Hepatol.
Polyzos, S. A., & Anastasilakis A. D. (2009).  Clinical complications following thyroid fine-needle biopsy: a systematic review.. Clin Endocrinol (Oxf). 71(2), 157-65.
Anastasilakis, A. D., Polyzos S. A., Makras P., Aubry-Rozier B., Kaouri S., & Lamy O. (2017).  Clinical Features of 24 Patients With Rebound-Associated Vertebral Fractures After Denosumab Discontinuation: Systematic Review and Additional Cases.. J Bone Miner Res. 32(6), 1291-1296.
Polyzos, S. A., & Terpos E. (2016).  Clinical vertebral fractures following denosumab discontinuation.. Endocrine. 54(1), 271-272.
Anastasilakis, A. D., Ruggeri R-M., Polyzos S. A., Makras P., Molyva D., Campennì A., et al. (2013).  Coexistence of Graves' disease, papillary thyroid carcinoma and unilateral benign struma ovarii: case report and review of the literature.. Metabolism. 62(10), 1350-6.
Polyzos, S. A., & Goulis D. G. (2011).  Coincidental thyroid papillary microcarcinoma in a patient treated for a toxic adenoma of the thyroid.. Arch Iran Med. 14(2), 149-51.
Nikolaidis, N., Polyzos S. A., Giouleme O., Katsinelos P., Eugenidis N., Zeglinas C., et al. (2016).  Colchicine to decrease inflammation and fibrosis in patients with metabolic dysregulation.. Med Hypotheses. 95, 34.
Anastasilakis, A. D., Polyzos S. A., Yavropoulou M. P., & Makras P. (2020).  Combination and sequential treatment in women with postmenopausal osteoporosis.. Expert Opin Pharmacother. 21(4), 477-490.
Makri, E. S., Makri E., & Polyzos S. A. (2022).  Combination Therapies for Nonalcoholic Fatty Liver Disease.. J Pers Med. 12(7), 
Kazakos, E. I., Dorrell N., Polyzos S. A., Deretzi G., & Kountouras J. (2017).  Comment on "Effect of biofilm formation by clinical isolates of Helicobacter pylori on the efflux-mediated resistance to commonly used antibiotics".. World J Gastroenterol. 23(33), 6194-6196.
Polyzos, S. A., Kountouras J., Zavos C., & Deretzi G. (2012).  Comment on: Jeon et al. Helicobacter pylori Infection Is Associated With an Increased Rate of Diabetes. Diabetes Care 2012;35:520-525.. Diabetes Care. 35(7), e53; author reply e54.
Kountouras, J., Polyzos S. A., Doulberis M., Stergiopoulos C., & Katsinelos P. (2018).  Comment on "Therapeutic Application of an Extract of Ameliorates the Development of Allergic Airway Disease".. J Immunol. 200(9), 3027.
Polyzos, S. A., Kang E. Seok, Tsochatzis E. A., Kechagias S., Ekstedt M., Xanthakos S., et al. (2020).  Commentary: Nonalcoholic or metabolic dysfunction-associated fatty liver disease? The epidemic of the 21st century in search of the most appropriate name.. Metabolism. 113, 154413.
Doulberis, M., Polyzos S. A., Papaefthymiou A., Katsinelos P., & Kountouras J. (2019).  Comments to the Editor concerning the paper entitled "The microbiome and ophthalmic disease" by Baim et al.. Exp Biol Med (Maywood). 244(6), 430-432.
Anagnostis, P., Adamidou F., Slavakis A., Polyzos S. A., Selalmatzidou D., Panagiotou A., et al. (2014).  Comparative Effect of Atorvastatin and Rosuvastatin on 25-hydroxy-Vitamin D Levels in Non-diabetic Patients with Dyslipidaemia: A Prospective Randomized Open-label Pilot Study.. Open Cardiovasc Med J. 8, 55-60.
Anastasilakis, A. D., Polyzos S. A., Yavropoulou M. P., Appelman-Dijkstra N. M., Ntenti C., Mandanas S., et al. (2021).  Comparative Effect of Zoledronate at 6 Versus 18 Months Following Denosumab Discontinuation.. Calcif Tissue Int.
Anastasilakis, A. D., Polyzos S. A., Gkiomisi A., Bisbinas I., Gerou S., & Makras P. (2013).  Comparative effect of zoledronic acid versus denosumab on serum sclerostin and dickkopf-1 levels of naive postmenopausal women with low bone mass: a randomized, head-to-head clinical trial.. J Clin Endocrinol Metab. 98(8), 3206-12.
Makri, E., Kita M., Goulas A., Papaioannidou P., Efstathiadou Z. A., Adamidou F., et al. (2020).  Comparative effectiveness of glucagon-like peptide-1 receptor agonists versus dipeptidyl peptidase-4 inhibitors on noninvasive indices of hepatic steatosis and fibrosis in patients with type 2 diabetes mellitus.. Diabetes Metab Syndr. 14(6), 1913-1919.

Pages

Contact

Secretariat of the School of Medicine
 

Connect

School of Medicine's presence in social networks
Follow Us or Connect with us.